Century Therapeutics, Inc.(IPSC)

$2.20—Stale · unknown old

Chart

Century Therapeutics, Inc.(IPSC)

NASDAQ • Last print unknown ago

$2.20—Stale · unknown old

Chart Studio

IPSC(IPSC)

IPSC

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.12

Nov 12, 2026 · Reports before open

Revenue Estimate

$2M

Analyst Sentiment

Wall St. Consensus

Buy

9 analysts·Limited coverage

Score

7 Buy (78%)2 Hold (22%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

778%

Hold

222%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

-9.1%

Consensus

$2.00

-9.1%

Bull

$2.00

-9.1%

12-Month Target Range9 analysts

$2.00$2.00$2.00

Current $2.20Consensus

Current Price

$2.20

Above Consensus

$0.20

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-20.90%

EPS—

FY2028

Rev-68.41%

EPS—

FY2029

Rev-68.22%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$5M	$4M	$1M	$375,000	$43M
Low	$5M	$4M	$1M	$375,000	$43M
High	$5M	$4M	$1M	$375,000	$43M
EBITDA Avg	$-2M	$-1M	$-464,535	$-147,627	$-17M
Low	$-2M	$-1M	$-464,535	$-147,627	$-17M
High	$-2M	$-1M	$-464,535	$-147,627	$-17M
EBIT Avg	$-2M	$-2M	$-492,857	$-156,628	$-18M
Low	$-2M	$-2M	$-492,857	$-156,628	$-18M
High	$-2M	$-2M	$-492,857	$-156,628	$-18M
Net Income Avg	$-43M	$-37M	$-31M	$-33M	$-31M
Low	$-50M	$-50M	$-33M	$-33M	$-31M
High	$-36M	$-25M	$-29M	$-33M	$-31M
EPS Avg	$-0.52	$-0.45	$-0.36	$-0.38	$-0.35
Low	$-0.58	$-0.57	$-0.38	$-0.38	$-0.35
High	$-0.41	$-0.29	$-0.34	$-0.38	$-0.35
Analysts (Rev / EPS)	4 / 3	5 / 3	3 / 2	1 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2M	$1M	—	—	—	—
Low	$2M	$1M	—	—	—	—
High	$2M	$1M	—	—	—	—
EBITDA Avg	$-643,000	$-472,408	—	—	—	—
Low	$-643,000	$-472,408	—	—	—	—
High	$-643,000	$-472,408	—	—	—	—
EBIT Avg	$-682,204	$-501,211	—	—	—	—
Low	$-682,204	$-501,211	—	—	—	—
High	$-682,204	$-501,211	—	—	—	—
Net Income Avg	$-25M	$-26M	$-25M	$-24M	$-24M	$-25M
Low	$-25M	$-26M	$-25M	$-24M	$-24M	$-25M
High	$-25M	$-24M	$-25M	$-24M	$-24M	$-25M
EPS Avg	$-0.12	$-0.13	$-0.12	$-0.12	$-0.12	$-0.12
Low	$-0.12	$-0.13	$-0.12	$-0.12	$-0.12	$-0.12
High	$-0.12	$-0.12	$-0.12	$-0.12	$-0.12	$-0.12
Analysts (Rev / EPS)	2 / 3	2 / 3	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Mar 13, 2026Leerink Partners

Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC)

Target:$2.00

-20.6%from $2.52

Jan 20, 2026Piper Sandler

Century Therapeutics price target raised to $4 from $2 at Piper Sandler

Target:$4.00

+84.3%from $2.17

Nov 6, 2024H.C. Wainwright

Century Therapeutics (IPSC) PT Lowered to $5 at H.C. Wainwright

Target:$5.00

+259.7%from $1.39

Apr 12, 2024Piper Sandler

Century Therapeutics (IPSC) PT Lowered to $9 at Piper Sandler

Target:$9.00

+122.2%from $4.05

Jan 5, 2023Piper Sandler

Century Therapeutics price target lowered to $14 from $24 at Piper Sandler

Target:$14.00

+189.3%from $4.84

Dec 27, 2022Chardan Capital

Century Therapeutics initiated with a Buy at Chardan

Target:$19.00

+235.1%from $5.67

Nov 14, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $25

Target:$25.00

+127.3%from $11.00

Apr 29, 2022Leerink Partners

SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27

Target:$27.00

+124.4%from $12.03

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance